CVS Health’s second-quarter results offer a sharp illustration of how quickly the economics of a health insurer can change when medical costs, pricing and membership begin moving in the same direction.
The company reported net income of $2.995 billion for the second quarter of 2026, up from $1.013 billion a year earlier. Revenue increased 7.3% to $106.1 billion, and adjusted earnings reached $2.58 a share.
Those numbers give CVS Health a stronger earnings story. The more consequential development sits inside Aetna.
CVS’s Health Care Benefits business, which includes Aetna, generated adjusted operating income of $2.426 billion during the quarter, an 85.5% increase from the prior-year period. The performance signals that a business responsible for some of CVS Health’s biggest financial concerns in recent years is moving in a different direction.
For insurers and brokers watching Medicare Advantage, the shift carries implications beyond CVS. It shows how aggressively large carriers can respond when rising utilization and medical costs weaken margins, and how quickly financial performance can recover when pricing and benefit decisions begin to catch up.
A $3 billion quarter puts Aetna back at the center
Aetna’s problems were never simply a question of revenue.
Health insurers can continue generating billions of dollars in premium income and still see profitability deteriorate rapidly when members use more care than expected. Medicare Advantage carriers have experienced that problem as utilization increased and medical expenses exceeded assumptions embedded in earlier pricing.
CVS Health spent much of the previous two years addressing that imbalance.
By the second quarter of 2026, the financial effect was becoming clearer. Health Care Benefits revenue reached $37.538 billion. Adjusted operating income climbed to $2.426 billion from $1.308 billion in the same quarter a year earlier.
Medical membership stood at 26 million at June 30, unchanged from the end of the first quarter.
The absence of rapid membership expansion is significant. The improvement is not simply the result of adding a large pool of customers. CVS has been working on the economics of the existing insurance book, including pricing, benefits and its exposure to different markets.
That distinction matters for insurance executives. Membership growth can produce an impressive top-line number, but growth priced below the eventual cost of care can destroy value. A carrier willing to sacrifice some enrollment or withdraw from underperforming markets can produce a healthier book even when membership growth slows.
The strategy is visible elsewhere in CVS’s portfolio.
The company left the individual Affordable Care Act exchange business for 2026. CVS cited that exit as one factor partially offsetting revenue growth in Health Care Benefits.
That was a selective withdrawal from a market that remains substantial. CMS reported that 23.1 million consumers selected or were automatically re-enrolled in exchange coverage during the 2026 open enrollment period. CVS’s departure therefore says more about its preferred risk and return profile than it does about the relevance of the ACA market.
The number that matters most is 87.4%
The clearest measure of Aetna’s progress is not net income. It is the medical benefit ratio.
CVS reported an MBR of 87.4% for Health Care Benefits during the second quarter, compared with 89.9% a year earlier.
The ratio measures benefit costs as a percentage of premium revenue. A lower figure means less of every premium dollar is being consumed by medical expenses, subject to the other factors contained in the calculation.
A movement of 2.5 percentage points can have an outsized effect at Aetna’s scale.
CVS attributed the improvement primarily to stronger underlying performance in its government business and the absence of a premium deficiency reserve recorded in the prior-year period. The company reported $1.2 billion of favorable development in prior years’ health care cost estimates during the first six months of 2026.
For the wider Medicare Advantage market, the result provides a useful case study in how carriers are responding to the medical cost environment.
When claims run above forecasts, insurers have a limited set of financial levers. They can increase premiums where the market allows it, revise benefits, change provider arrangements, adjust geographic participation or accept weaker margins. Medicare Advantage adds another layer of complexity through government reimbursement and star ratings.
The response can create tension between growth and profitability.
An insurer seeking maximum membership may tolerate thinner margins for longer. A company under pressure to repair earnings can take a harder position on pricing and market participation. CVS’s recent decisions suggest it has moved closer to the second camp.
Its ACA withdrawal reinforces that reading. Aetna’s improving government-business results show where the company sees a more attractive route toward sustainable insurance earnings.
The question for competitors is whether comparable margin improvement can be achieved without materially weakening products or losing desirable members.
Aetna’s recovery does not settle the CVS Health story
CVS Health now expects adjusted earnings of $7.90 to $8.10 a share for 2026, up from its previous forecast of $7.30 to $7.50. The company raised its operating cash flow forecast to at least $11.5 billion.
That is a substantial change in expectations, but the second-quarter performance does not make medical cost pressure disappear.
CVS continues to flag elevated medical cost trends as a risk. Its integrated structure creates another complication. Stronger insurance results need to be considered alongside the economics of its pharmacy, pharmacy benefit management and care delivery operations.
This is what makes the Aetna turnaround more interesting than a conventional earnings rebound.
CVS bought Aetna to create a health care company with insurance, pharmacy benefits, retail pharmacy and clinical services under one corporate structure. The theory rests partly on those businesses producing advantages that they could not obtain independently. Years of medical cost pressure showed that integration does not remove the underlying insurance cycle.
Aetna’s 2026 performance shows a different side of the model. When the insurance operation is priced more effectively and claims move closer to expectations, CVS receives the earnings contribution it originally expected from a major health plan.
That puts Medicare Advantage back near the center of the CVS investment case.
The next test is less dramatic than tripling quarterly net income. CVS must show that Aetna can maintain disciplined medical economics after the easiest year-over-year comparisons disappear.
If the 87.4% benefit ratio proves repeatable rather than temporary, the second quarter will mark more than a strong earnings period. It will show that CVS has found a more workable balance between insurance growth and the price of taking health care risk.
Source
